Get the Stockscreener App
0.00
100.00%
-6.365
Cyclacel Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$6.365
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$15.16M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
0.00
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$19.87
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.00 | 15.16M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Market Review: Can Cyclacel Pharmaceuticals Inc. stock hit analyst price targetsStock Surge & Verified Momentum Stock Ideas - moha.gov.vn
Cyclacel Pharmaceuticals Inc Stock Analysis and ForecastResistance Breakout Alerts & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Cyclacel Pharmaceuticals (BGMS) Stock Chart and Price History 2025 - MarketBeat
Cyclacel Pharmaceuticals (BGMS) Stock Trends and Sentiment 2025 - MarketBeat
Cyclacel Pharmaceuticals (BGMS) Competitors and Alternatives 2025 - MarketBeat
Should I hold or sell Cyclacel Pharmaceuticals Inc. stock in 20252025 Big Picture & Real-Time Volume Surge Alerts - newser.com
Cyclacel Pharmaceuticals (NASDAQ:BGMS) Rating Increased to Hold at Wall Street Zen - Defense World
Cyclacel Pharmaceuticals (BGMS) Stock Price, News & Analysis - MarketBeat
How Cyclacel Pharmaceuticals Inc. stock trades during market volatilityJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
Is Cyclacel Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Institutional & Long-Term Investment Growth Plans - newser.com
Is Cyclacel Pharmaceuticals Inc. stock resilient to inflation2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - newser.com
Visual analytics tools that track Cyclacel Pharmaceuticals Inc. performance2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Can Cyclacel Pharmaceuticals Inc. stock deliver surprise earnings beatEntry Point & Risk Managed Investment Signals - newser.com
Is Cyclacel Pharmaceuticals Inc. stock attractive for passive investorsWeekly Risk Summary & High Yield Equity Trading Tips - newser.com
Why Cyclacel Pharmaceuticals Inc. stock is popular among millennialsPortfolio Gains Report & Long Hold Capital Preservation Plans - newser.com
Will Cyclacel Pharmaceuticals Inc. stock reach all time highs in 2025 - newser.com
Order flow analysis tools used on Cyclacel Pharmaceuticals Inc.Portfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Published on: 2025-11-16 16:56:09 - newser.com
Evaluating Cyclacel Pharmaceuticals Inc. with trendline analysisJuly 2025 Levels & Weekly Return Optimization Alerts - newser.com
What to do if you’re stuck in Cyclacel Pharmaceuticals Inc.Weekly Risk Summary & Safe Capital Growth Stock Tips - newser.com
Can Cyclacel Pharmaceuticals Inc. stock resist sector downturnsGap Up & High Yield Stock Recommendations - newser.com
Can trapped investors hope for a rebound in Cyclacel Pharmaceuticals Inc.Market Risk Report & Daily Stock Momentum Reports - newser.com
Will Cyclacel Pharmaceuticals Inc. stock see insider buyingIndex Update & AI Enhanced Trading Alerts - newser.com
Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Is Cyclacel Pharmaceuticals Inc. stock a good choice for value investorsQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Bio Green Med Solution’s Strategic Shift and Q3 Results - TipRanks
[10-Q] Bio Green Med Solution, Inc. Quarterly Earnings Report | BGMS SEC FilingForm 10-Q - Stock Titan
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cyclacel Pharmaceuticals Inc Stock (CYCC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yap Kim Choy | 10% Owner |
Oct 30 '25 |
Sale |
1.81 |
112,260 |
202,854 |
28,500 |
| Kua Khai Loon | 10% Owner |
Oct 30 '25 |
Sale |
1.80 |
242,477 |
436,459 |
0 |
| Ong Yee Lung | 10% Owner |
Oct 30 '25 |
Sale |
1.80 |
248,814 |
447,865 |
0 |
| Yap Kim Choy | 10% Owner |
Oct 29 '25 |
Sale |
1.83 |
110,749 |
203,114 |
140,760 |
| Yap Kim Choy | 10% Owner |
Oct 28 '25 |
Sale |
1.83 |
13,111 |
23,967 |
251,509 |
| Yap Kim Choy | 10% Owner |
Oct 27 '25 |
Sale |
2.12 |
120,250 |
254,690 |
264,620 |
| Ong Yee Lung | 10% Owner |
Oct 24 '25 |
Sale |
1.99 |
19,858 |
39,517 |
248,814 |
| Yap Kim Choy | 10% Owner |
Oct 24 '25 |
Sale |
1.90 |
19,595 |
37,270 |
384,870 |
| FITTERS Diversified Berhad | 10% Owner |
Oct 21 '25 |
Sale |
3.00 |
92,352 |
277,518 |
279,248 |
| FITTERS Diversified Berhad | 10% Owner |
Oct 20 '25 |
Sale |
3.09 |
108,107 |
333,834 |
371,600 |
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):